Elicio Therapeutics (ELTX) Current Deferred Revenue (2020 - 2025)

Elicio Therapeutics (ELTX) has 6 years of Current Deferred Revenue data on file, last reported at $680000.0 in Q1 2025.

• For the quarter ending Q1 2025, Current Deferred Revenue rose 8.45% year-over-year to $680000.0; the trailing twelve-month figure through Mar 2025 stood at $680000.0 (up 8.45% YoY), and the FY2024 full-year result was $1.2 million, up 68.44% from the prior year.
• Current Deferred Revenue for Q1 2025 stood at $680000.0, down from $1.2 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $5.2 million in Q2 2021 and bottomed at $400000.0 in Q2 2024.
• The 5-year median for Current Deferred Revenue is $1.3 million (2022), against an average of $1.9 million.
• The widest annual swing landed in 2022, when Current Deferred Revenue slumped 82.78%; it then jumped 68.44% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $2.3 million in 2021, then slumped by 37.59% to $1.4 million in 2022, then slumped by 51.67% to $694000.0 in 2023, then surged by 68.44% to $1.2 million in 2024, then tumbled by 41.83% to $680000.0 in 2025.
• The last three Current Deferred Revenue figures came in at $680000.0 (Q1 2025), $1.2 million (Q4 2024), and $400000.0 (Q2 2024), per Business Quant data.

Peer Comparison